Anteris Technologies Ltd
ASX:AVR

Watchlist Manager
Anteris Technologies Ltd Logo
Anteris Technologies Ltd
ASX:AVR
Watchlist
Price: 9.3 AUD -3.93% Market Closed
Market Cap: 196.6m AUD
Have any thoughts about
Anteris Technologies Ltd?
Write Note

Anteris Technologies Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Anteris Technologies Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Anteris Technologies Ltd
ASX:AVR
Income from Continuing Operations
-AU$68.9m
CAGR 3-Years
-65%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Income from Continuing Operations
AU$13m
CAGR 3-Years
15%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Polynovo Ltd
ASX:PNV
Income from Continuing Operations
AU$5.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SDI Ltd
ASX:SDI
Income from Continuing Operations
AU$10.4m
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
5%
Ansell Ltd
ASX:ANN
Income from Continuing Operations
$77.5m
CAGR 3-Years
-32%
CAGR 5-Years
-7%
CAGR 10-Years
6%
Next Science Ltd
ASX:NXS
Income from Continuing Operations
-$16.3m
CAGR 3-Years
-11%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Anteris Technologies Ltd
Glance View

Market Cap
178.8m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.76 AUD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Anteris Technologies Ltd's Income from Continuing Operations?
Income from Continuing Operations
-68.9m AUD

Based on the financial report for Dec 31, 2023, Anteris Technologies Ltd's Income from Continuing Operations amounts to -68.9m AUD.

What is Anteris Technologies Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-23%

Over the last year, the Income from Continuing Operations growth was -55%. The average annual Income from Continuing Operations growth rates for Anteris Technologies Ltd have been -65% over the past three years , -23% over the past five years .

Back to Top